Zevra Therapeutics (ZVRA) Return on Equity (2015 - 2026)

Zevra Therapeutics has reported Return on Equity for 12 years, with the latest figure at 0.01% in Q1 2026.

• For the quarter ending Q1 2026, Return on Equity rose 3.0% year-over-year to 0.01%; the trailing twelve-month figure through Mar 2026 stood at 0.01% (up 3.0% YoY), and the FY2025 full-year result was 0.01%, up 3.0% from the prior year.
• Return on Equity for Q1 2026 stood at 0.01%, up from 0.01% in the prior quarter.
• The five-year high for Return on Equity was 0.01% in Q1 2026, with the low at 0.02% in Q1 2025.
• Historically, Return on Equity has averaged 0.01% across 5 years, with a median of 0.01% in 2024.
• Annual changes were most pronounced in 2022 — Return on Equity slipped 1 bps — and 2025, when it increased 3 bps.
• Zevra Therapeutics' Return on Equity stood at 0.01% in 2022, then declined by 20 bps to 0.01% in 2023, then plunged by 158 bps to 0.02% in 2024, then jumped by 130 bps to 0.01% in 2025, then climbed by 19 bps to 0.01% in 2026.
• The last three Return on Equity figures came in at 0.01% (Q1 2026), 0.01% (Q4 2025), and 0.0% (Q3 2025), per Business Quant data.